Eliem Therapeutics, Inc.
NASDAQ:ELYM
5.11 (USD) • At close October 2, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 6.575 | 17.327 | 8.912 | 6.087 | 1.046 | 1.091 | 3.127 | 2.876 | 3.688 | 5.72 | 4.927 | 4.258 | 8.769 | 8.26 | 6.879 | 5.989 | 5.793 | 4.661 | 4.412 | 1.947 | 1.36 | 1.623 |
| General & Administrative Expenses
| 4.102 | 5.691 | 8.449 | 5.492 | 3.667 | 1.914 | 1.995 | 2.125 | 3.026 | 17.718 | 4.627 | 4.49 | 4.932 | 4.872 | 3.824 | 3.394 | 2.914 | 2.218 | 1.537 | 0.312 | 0.248 | 0.328 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 4.102 | 5.691 | 8.449 | 5.492 | 3.667 | 1.914 | 1.995 | 2.125 | 3.026 | 17.718 | 4.627 | 4.49 | 4.932 | 4.872 | 3.824 | 3.394 | 2.914 | 2.218 | 1.537 | 0.312 | 0.248 | 0.328 |
| Other Expenses
| 0 | 0 | 51.819 | 0.153 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.085 | 0.06 | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 10.677 | 23.018 | 69.18 | 11.732 | 4.713 | 3.005 | 5.122 | 5.001 | 6.714 | 23.438 | 9.554 | 8.748 | 13.701 | 13.132 | 10.703 | 9.383 | 8.707 | 6.879 | 5.949 | 2.259 | 1.608 | 1.951 |
| Operating Income
| -10.677 | -23.018 | -62.57 | -11.732 | -4.713 | -3.005 | -5.122 | -5.001 | -6.714 | -23.438 | -9.554 | -8.748 | -13.701 | -13.132 | -10.703 | -9.383 | -8.707 | -6.879 | -15.107 | -2.259 | -1.608 | -1.951 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 2.011 | 2.237 | 0 | 2.837 | -50.176 | 1.308 | 1.481 | 1.033 | 1.494 | 1.148 | 1.792 | -0.934 | -0.895 | -0.072 | 0.158 | -0.232 | -0.012 | -11.722 | -8.914 | 0.001 | -0.023 | 0.035 |
| Income Before Tax
| -8.666 | -20.781 | -8.416 | -8.895 | -54.889 | -1.697 | -3.641 | -3.968 | -5.22 | -22.29 | -7.762 | -9.682 | -14.596 | -13.204 | -10.545 | -9.615 | -8.719 | -18.601 | -14.863 | -2.258 | -1.631 | -1.916 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 3.008 | 0 | 0 | 0 | -0.003 | -0.005 | 0 | -1.148 | -1.792 | 0 | 0.895 | 0.072 | 0 | 0 | 0 | 0 | -9.158 | 0 | 0 | 0 |
| Net Income
| -8.666 | -20.781 | -8.416 | -8.895 | -54.889 | -1.697 | -3.641 | -3.968 | -5.22 | -21.142 | -5.97 | -9.682 | -15.491 | -13.276 | -10.545 | -9.615 | -8.719 | -18.601 | -14.863 | -2.258 | -1.631 | -1.916 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.13 | -0.31 | 0.47 | -0.13 | -1.81 | -0.061 | -0.13 | -0.15 | -0.19 | -0.8 | -0.23 | -0.37 | -0.59 | -0.51 | -0.4 | -0.62 | -0.37 | -1.6 | -1.27 | -0.19 | -0.14 | -0.16 |
| EPS Diluted
| -0.13 | -0.31 | 0.47 | -0.13 | -1.81 | -0.061 | -0.13 | -0.15 | -0.19 | -0.8 | -0.23 | -0.37 | -0.59 | -0.51 | -0.4 | -0.62 | -0.37 | -1.6 | -1.27 | -0.19 | -0.14 | -0.16 |
| EBITDA
| -10.677 | -23.018 | -10.911 | -11.732 | -56.372 | -3.005 | -5.122 | -5.001 | -6.714 | -23.438 | -6.154 | -8.748 | -13.701 | -13.132 | -10.703 | -9.383 | -8.707 | -6.875 | -5.949 | -0.46 | -0.475 | -0.404 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |